Metacam

1 x 10 ml

Liquid for injection, solution

Active substance

Meloxicam : 2 mg/ml

ATC code

QM01AC06 Meloxicam

QM01AC Oxicams

QM01A Antiinflammatory and antirheumatic products, non-steroids (NSAIDs)

QM01 Antiinflammatory and antirheumatic products

QM Musculo-skeletal system

Species

Cats

Indications

Alleviation of mild to moderate post-operative pain and inflammation following surgical procedures in cats, e.g. orthopaedic and soft tissue surgery.

Dose to be administered and administration route

Reduction of post-operative pain and inflammation when administration of meloxicam is to be continued as an oral follow-up therapy:

Single subcutaneous injection at a dosage of 0.2 mg meloxicam/kg body weight (i.e. 0.1 ml/kg body weight) before surgery, for example at the time of induction of anaesthesia.

To continue treatment for up to five days, this initial dose may be followed 24 hours later by administration of Metacam 0.5 mg/ml oral suspension for cats at a dosage of 0.05 mg meloxicam/kg body weight. The oral follow-up dose may be administered for up to a total of four doses at 24 hour intervals.

Reduction of post-operative pain and inflammation where no oral follow-up treatment is possible e.g. feral cats:

Single subcutaneous injection at a dosage of 0.3 mg meloxicam/kg body weight (i.e. 0.15 ml/kg body weight) before surgery, for example at the time of induction of anaesthesia. In this case do not use oral follow up treatment.

Particular care should be taken with regard to the accuracy of dosing. To ensure a correct dosage, body weight should be determined as accurately as possible. The use of suitably calibrated measuring equipment is recommended.

Avoid introduction of contamination during use.

Adverse reactions

Cats:

Very rare

(< 1 animal in 10,000 animals treated, including isolated reports).

Appetite loss¹, lethargy¹

Vomiting¹, diarrhoea¹, blood in faeces^1,2, haemorrhagic diarrhoea¹, haematemesis¹,

gastric ulcer¹, small intestinal ulcer¹

Elevated liver enzymes¹

Renal failure¹

Anaphylactoid reaction³

¹ These adverse events occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.

² Occult

³ Should be treated symptomatically.

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.